Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended

2023-508528-36-00 Resected squamous cell carcinoma of the head and neck 5 2022-12-16
Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Ep… Ended

2024-513230-38-00 Platinum-Resistant Epithelial Ovarian, Fallopian Tube, 5 2022-12-15
A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12) Ended

2024-511116-25-00 Multiple Myeloma 1 2022-12-13
Multicentre, Phase 3 Trial to Determine Diagnostic Value of 68Ga-PSMA-11 (in PET/CT and PET/MRI) in Intermediate and High-Risk Prostate Canc… Ended

2024-516556-17-00 Intermediate and high-risk prostate cancer 5 2022-12-12
A First-in-Human Clinical Study with ABBV-CLS-579 alone and in combination in Patients with Advanced Tumor Cancers Ended

2023-507432-20-00 Metastatic or locally advanced tumors 1 2022-12-10
Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhi… Ended

2022-500652-37-00 Advanced melanoma refractory to prior checkpoint inhibi 4 2022-12-01
A study to test whether BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder Ended

2023-506369-79-00 Pancreatic ductal adenocarcinoma 4 2022-11-30
Phase I study of MGY825 in patients with lung cancer Ended

2023-504350-36-00 Advanced non-small cell lung cancer with or without NFE 1 2022-11-25
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumors Ended

2024-512710-17-00 Advanced solid tumors 1 2022-11-22
Neoadjuvant Chemotherapy followed by Pre-operative Chemoradiation and Consolidation Chemotherapy before Surgery in High Risk Rectal Cancer: … Ended

2024-517183-31-00 High Risk Rectal Cancer 4 2022-11-18
DT-9081 trial in participants with advanced solid tumours. Ended

2024-516206-28-00 Participants with advanced ( unresectable, recurrent or 1 2022-11-17
Seamless Phase 2/3 Study of Ibrutinib With Rituximab in Relapsed/Refractory Mantle Cell Lymphoma Ended

2023-503618-64-00 Relapsed/Refractory Mantle Cell Lymphoma 4 2022-11-16
Study to evaluate the impact of VCN-01 on the overall survival of patients with advanced pancreatic cancer treated with standard therapy. Ended

2024-511290-30-00 Metastatic Pancreatic Cancer 4 2022-11-15
Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat… Ended

2024-514714-12-00 Metastatic Pancreatic Ductal Adenocarcinoma 10 2022-11-11
PEARLDIFER - A Phase II study of pemigatinib after curative local therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) harbori… Ended

2024-512018-16-00 locally advanced intrahepatic cholangiocarcinoma (iCCA) 4 2022-11-11
Trial investigating a personalized treatment, based on age and tumor characteristics , of newly diagnosed medullablastoma in patients that a… Ended

2023-506193-12-00 Newly Diagnosed Medulloblastoma 4 2022-11-10
Digoxin for the Reinduction or Radioiodine Uptake in Metastatic or Locally Advanced Non-medullary Thyroid Cancer. Ended

2022-500477-14-00 Non-medullary thyroid Carconoma (NMTC) 4 2022-11-09
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors Ended

2022-500094-14-00 gastroesophageal junction [GEJ] carcinoma 1 2022-11-08
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia Ended

2023-507748-35-00 Acute Myeloid Leukemia 1 2022-11-08
Study of safety and antitumor activity of GEN1056 in participants with advanced solid tumors Ended

2024-514357-29-00 Advanced solid tumors 1 2022-11-04
Study to evaluate the efficacy and safety of fedratinib in combination with CC-486 in patients suffering from myelofibrosis in acute phase. Ended

2024-519227-22-00 Myeloproliferative neoplasm in accelerated phase (MPN-A 9 2022-11-03
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy and in Com… Ended

2022-502419-12-00 Malignant Solid Tumors 7 2022-11-02
Study to see how safe is TNG908 at different doses in patients with solid tumors that have a gene called MTAP missing Ended

2024-511976-34-00 "Ph1: •Locally advanced (LA) or metastatic MTAP-deleted 7 2022-10-31
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Ended

2023-508404-37-00 Non-muscle Invasive Bladder Cancer 3 2022-10-26